Tachykinin antagonists
    21.
    发明授权
    Tachykinin antagonists 失效
    速激肽拮抗剂

    公开(公告)号:US5554627A

    公开(公告)日:1996-09-10

    申请号:US428065

    申请日:1995-04-27

    摘要: Compounds of formula (I), wherein Q.sup.1 represents an aryl group; the dotted line represents an optional covalent bond; one of X and Y represents H and the other represents hydroxy or C.sub.1-6 alkoxy, or X and Y together form a group .dbd.O or .dbd.NOR.sup.5 where R.sup.5 is H or C.sub.1-6 alkyl; Z represents O, S or NR.sup.2, where R.sup.2 is H or C.sub.1-6 alkyl; W represents a bond or a saturated or unsaturated hydrocarbon chain of 1, 2, 3, 4, 5 or 6 carbon atoms; R.sup.1 represents H or C.sub.1-6 alkyl. R.sup.3 represents H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl; R.sup.4 represents an optionally substituted phenyl group; and R.sup.6 represents a specified amino group or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group; and salts and prodrugs are tachykinin receptor antagonists.

    摘要翻译: PCT No.PCT / GB93 / 02213 371日期:1995年04月27日 102(e)日期1995年4月27日PCT提交1993年10月27日PCT公布。 公开号WO94 / 10167 (I)其中Q1表示芳基的式(I)化合物; 虚线表示任选的共价键; X和Y之一表示H,另一个表示羟基或C 1-6烷氧基,或X和Y一起形成基团= O或= NOR5,其中R5是H或C1-6烷基; Z表示O,S或NR2,其中R2是H或C1-6烷基; W表示具有1,2,3,4,5或6个碳原子的键或饱和或不饱和烃链; R1表示H或C1-6烷基。 R 3表示H,C 1-6烷基或C 2-6烯基; R4表示任选取代的苯基; 并且R 6表示指定的氨基或任选取代的芳族或非芳族氮杂环或氮杂双环基; 盐和前药是速激肽受体拮抗剂。

    6-Oxa-1-aza tricyclo dodecan-5-ones as psychomotor stimulators
    26.
    发明授权
    6-Oxa-1-aza tricyclo dodecan-5-ones as psychomotor stimulators 失效
    6-Oxa-1-氮杂三环十二烷-5-酮作为精神运动刺激物

    公开(公告)号:US4083985A

    公开(公告)日:1978-04-11

    申请号:US655650

    申请日:1976-02-06

    CPC分类号: C07D453/02

    摘要: Compounds of the general formula ##STR1## wherein X is selected from the group consisting of oxygen CH.sub.2 and CH radicals, and when X designates oxygen, R designates alkyl, isoalkyl, aralkyl, and substituted aryl groups and when X designates ##STR2## then R designates alkyl, phenyl or substituted phenyl group, and A--B is a single bond and when X designates >CH, and A--B is a double bond, R designates alkyl, phenyl or substituted phenyl groups and physiologically acceptable salts of these, and pharmaceutical compositions containing same as active ingredient.

    摘要翻译: 通式为其中X选自氧CH 2和CH基团的通式为其中的化合物,当X表示氧时,R表示烷基,异烷基,芳烷基和取代的芳基,当X表示时, R表示烷基,苯基或取代的苯基,AB是单键,当X表示> CH时,AB表示双键,R表示烷基,苯基或取代的苯基及其生理学上可接受的盐, 与活性成分相同。

    Processes and intermediates for quinine, quinidine and analogs thereof
    27.
    发明授权
    Processes and intermediates for quinine, quinidine and analogs thereof 失效
    奎宁,奎尼丁及其类似物的方法和中间体

    公开(公告)号:US3907806A

    公开(公告)日:1975-09-23

    申请号:US46642274

    申请日:1974-05-02

    申请人: HOFFMANN LA ROCHE

    摘要: Quinine, quinidine and analogs thereof, are prepared by reacting a 4-quinolyllithium compound with a 4,5-erythro-5-ethyl(or vinyl)-quinuclidine-2 xi -carboxaldehyde or the corresponding quinuclidine-2-carboxylic acid alkyl ester. Also described, inter alia, is the preparation of a 4,5-erythro-5-ethyl(or vinyl)quinuclidine-2 xi -carboxaldehyde, and a 4,5-erythro-5-ethyl(or vinyl)-quinuclidine-2 xi -carboxylic acid and esters thereof. The end products are useful as antimalarial and antiarrhythmic agents.

    摘要翻译: 奎宁,奎尼丁及其类似物通过4-喹喔啉锂化合物与4,5-赤-5-乙基(或乙烯基) - 奎宁环-2x-甲醛或相应的奎宁环-2-羧酸烷基酯的反应来制备。 还描述了除其他之外,制备4,5-赤型-5-乙基(或乙烯基) - 奎宁环-2X-甲醛和4,5-赤型-5-乙基(或乙烯基) - 奎宁环 - 2×羧酸及其酯。 最终产品可用作抗疟和抗心律失常剂。

    Tyrosine kinase inhibitors
    30.
    发明授权

    公开(公告)号:US10851093B2

    公开(公告)日:2020-12-01

    申请号:US16424619

    申请日:2019-05-29

    摘要: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, X, Y1, Y2, Y3 and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.